BioSpace

In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t — and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsJennifer McMahon, Partner, SerobaJoey Mason, Venture Partner, Claret CapitalDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?

In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.Host⁠Jennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsMax Bronstein, CEO, Aviva StrategiesTeresa Barnes, Chief Executive Warrior, PF WarriorsDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.

In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of Global Clinical Development. We examine radioligand therapy’s accelerating momentum and how its diagnostic and therapeutic reach could potentially reshape care for more than 14 million patients worldwide.We also discuss Curium's push to expand US capacity and scale up at pace, and critically what success could mean for patients with cancer in the years ahead.This episode is presented in partnership with Curium.HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestsMike Patterson, CEO North America, Curium Sabine Brookman-May, VP and Head of Global Clinical Development, Curium Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.